Clinical trials: High-Risk Cancer
Uterine Cancer, Endometrial Carcinoma
A Study of Nivolumab in Selected Uterine Cancer Patients
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer.
- Conditions
- Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma
- Trial name
- NCT03241745
- Testing
- Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Adenocarcinoma, Stage I Prostate Cancer
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02346253
- Testing
- Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Stanford University
Triple Negative Breast Cancer
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H…
- Trial name
- NCT03562637
- Testing
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 575 people
- Sponsor
- OBI Pharma, Inc
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
- Trial name
- NCT02765997
- Testing
- Unmanipulated UCB, SR-1 UCB
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Peripheral Blood Stem Cell Transplantation
Ruxolitinib and Decitabine for High Risk Hematological Malignancies
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing allogeneic peripheral blood stem…
- Trial name
- NCT04582604
- Testing
- modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
High-risk Muscle Invasive Urothelial Carcinoma
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection.
- Trial name
- TU-04 (NCT07720284)
- Testing
- Dato-DXd, Rilvegostomig, Durvalumab
- Where
- 160 sites in United States, Australia and 14 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Enteral Nutrition, Cancer
2kcal Tube Feed Study
The primary aim of this study is to investigate the effects of a plant-based, high energy, high protein tube feed with and without inclusion of fibre on gastrointestinal tolerance in adult patients who require nutritional support…
- Trial name
- NCT05411848
- Testing
- 2kcal HP PlantBased
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Nutricia UK Ltd
Brain and Central Nervous System Tumors
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00253448
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Skin Rash
Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation
We are approaching you to participate in this study because you are taking Palifermin and the purpose of this study is to describe the effect of Palifermin on skin growth found on the body.
- Trial name
- Palifermin (NCT00610818)
- Testing
- Palifermin
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metastatic Melanoma
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Purpose of this Pilot Study: The investigators want to study the safety, side effects, and benefits of tumor infiltrating lymphocytes (TILs), when they are given with the drug ipilimumab.
- Trial name
- NCT01701674
- Testing
- Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA.
- Trial name
- NCT06493552
- Testing
- SEphB4-HSA, Pembrolizumab, Gemcitabine
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Vasgene Therapeutics, Inc
Leukemia, Myeloid, Acute
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT05682755
- Testing
- Chidamide
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Sichuan University
Neoplasms, Head and Neck
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with head and neck cancer following surgery.
- Trial name
- NCT00424255
- Testing
- Lapatinib, Chemoradiation
- Where
- 117 sites in United States, Argentina and 20 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
One important approach to change the natural history of advanced breast cancer is that of designing new combination chemotherapies in which the best drugs already available are used together with new anticancer agents devoid of…
- Trial name
- NCT00367250
- Testing
- Cetuximab, Trastuzumab
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
Squamous Cell Carcinoma of the Head and Neck
Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion
The general aim is to compare the cumulative dose of cisplatin administered concomitantly with radiotherapy in reference arm A (cisplatin 100 mg / m2 day 1 every 21 days) and in the experimental arm B (Cisplatin split 25 mg / m2…
- Trial name
- CisFRad (NCT03330249)
- Testing
- Split Cisplatin, Cisplatin, Radiotherapy
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase Ib trial studies the side effects and best dose of nivolumab and ipilimumab after donor stem cell transplant in treating patients with high risk acute myeloid leukemia or myelodysplastic syndrome that does not respond…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03600155
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple myeloma (MM) is a common incurable blood cancer causing debilitating symptoms-bone pain, kidney failure, low blood counts and infection.
- Trial name
- NCT02331368
- Testing
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Background: Human papillomavirus (HPV) can cause vulvar high-grade squamous intraepithelial lesions (HSIL). Sometimes, this can become cancer. Researchers want to see if T cell therapy can treat vulvar HSIL.
- Conditions
- Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
- Trial name
- NCT03937791
- Testing
- E7 T Cell Receptor (TCR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)
5G-PEARL: Paxalisib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy.
- Trial name
- 5G-PEARL (NCT07391215)
- Testing
- Paxalisib, Temozolomide capsule
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Institute of Cancer Research, United Kingdom
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.